Braxia Scientific Corp.
BRAX.CN News Today: Stay Updated with the Latest Braxia Scientific Corp. News in Real Time
Find BRAX.CN news now at Meyka AI. Stay informed with the latest Braxia Scientific Corp. stocks updates, including price news, market analysis, and expert insights.
Market closed: NTT, Inc. (9432.T JPX) JPY 155.90 01 Apr 2026: active, 3.03% div
9432.T stock review: NTT closes JPY 155.90 on 01 Apr 2026 with heavy volume and steady 3.03% dividend
MM.CN Metallica Metals Corp. (CNQ) +68% to C$0.32 01 Apr 2026: watch volume
MM.CN stock jumps 68% to C$0.32 on heavy volume 01 Apr 2026; analysis, Meyka grade, and C$1.17 forecast
Chris Rokos Supports Cambridge University with £190m Donation
A historic moment in British education and philanthropy has unfolded after billionaire investor Chris Rokos pledged a record-breaking £190 million donation to the University of Cambridge. The contribution represents the largest individual gift made to a UK university in modern history and signals a major investment in future leadership, governance education, and global policy research….
ALNEV.PA Neovacs S.A. EURONEXT +20% pre-market 01 Apr 2026: watch volume
ALNEV.PA stock jumps 20% to €0.0006 pre-market on heavy volume; analysis, Meyka grade and forecast
EOM.CN Eco Oro Minerals (CNQ) up 80% on heavy volume 401000 01 Apr 2026: Monitor catalysts
EOM.CN stock jumps 80% to C$0.045 on heavy volume; fundamentals weak but short-term catalysts support a cautious outlook
AMMP.CN AmmPower Corp. CNQ 31 Mar 2026: Shares at C$0.03 signal oversold bounce
AMMP.CN stock trades at C$0.03 on CNQ. Oversold bounce setup with heavy volume and model forecast C$0.06 upside.
Pre-market Most Active: 9434.T SoftBank JPX JPY 211.10 01 Apr 2026: high volume
Pre-market update on 9434.T stock at JPY 211.10 with high volume and analyst context from Meyka AI
March 31: Iran-Israel ‘camera hacks’ raise Hormuz oil and cyber risk
Iran Israel war oil risk rises as hacked surveillance cameras and a strike near the Strait of Hormuz elevate energy market risk and US cyber concerns.
Biogen to Buy Apellis in $5.6 Billion All‑Cash Deal
Biotech giant Biogen announced a major deal to acquire Apellis Pharmaceuticals for $5.6 billion in cash, marking one of the largest strategic transactions in the sector this year. The acquisition is aimed at strengthening Biogen’s drug pipeline, especially in areas such as eye disease and immunology where Apellis has developed promising therapies. Investors reacted strongly…